Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Supply Chain Clause of Economic Security Law Now in Effect
August 2, 2022
- MHLW Presents Plan for Monkeypox Vaccinations with KM Biologics’ Jab
August 2, 2022
- Japan OKs FY2023 Budget Guidelines, 560 Billion Yen Cap for Social Security Cost Rise
August 1, 2022
- Taisho/Ablynx’s RA Med, BI’s Psoriasis Drug Clear MHLW Panel, September Approval Likely
August 1, 2022
- MHLW Flags Hoarding of Acetaminophen, Ayumi Stops Supply of 2 Dosage Forms
August 1, 2022
- PMDA Reviewing Safety Risks for Plaquenil, Cyramza
August 1, 2022
- KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
- New Expert Panel to Issue Proposals for 2023, 2024 Price Revisions; Official Spearheading Debate Prods Industry to Speak Up
July 29, 2022
- Online Submissions for Partial Changes of Generics to Start from October
July 29, 2022
- MHLW Panel OKs 60 More Health Damage Claims for COVID-19 Vaccines
July 29, 2022
- Japan Detects 2nd Monkeypox Case in Tokyo
July 29, 2022
- Supply Chain Clause of Economic Security Law to Be Enforced on Aug. 1
July 28, 2022
- MHLW Eyes Omicron-Specific Jabs for All Residents Given Primary Inoculations
July 26, 2022
- Panel OKs COVID-Flu Shots to Be Given Simultaneously
July 26, 2022
- Japan Panel Recognizes 1st Death Linked to COVID Vaccination
July 26, 2022
- 8 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 26, 2022
- Japan Confirms 1st Monkeypox Case
July 26, 2022
- 4th COVID Jabs Approved for Healthcare Providers: MHLW
July 25, 2022
- Omicron-Specific Boosters to Be Introduced This Fall or Later: Panel
July 25, 2022
- KM Biologics’s Smallpox Vaccine Up for Review for Monkeypox Use
July 25, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…